Léčba mitoxantronem u rychle progredující roztroušené sklerózy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F05%3A00014829" target="_blank" >RIV/00216224:14110/05:00014829 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Mitoxantrone therapy in rapidly worsening multiple sclerosis

Popis výsledku v původním jazyce

The aim of the study was to asses the effect and safety of mitoxantrone (MX) therapy in patients with relapsing remitting and secondary progressive multiple sclerosis (MS). Thirty-three patients (10 males, 23 females, mean age 48.5+/-9.9 years) with relapsing remitting and secondary progressive MS were followed. The disability was evaluated using Expanded Disability Status Scale (EDSS). The mean time period from the onset to secondary progressive course of the disease was 9.3+/-9.8 years. Patients, whose disability progression increased by one or more EDSS points per one year, and who did not respond to other therapy, were treated with mitoxantrone. Patients were treated once monthly with intravenous administration of mitoxantrone 12 mg/m2 (not exceeding the maximum cumulative dose of 140 mg/m2) and methylprednisolone 1000 mg. Six pulses were administered in each patient. EDSS score was measured at the beginning of the treatment and after twelve months. Disability progression was evalu

Název v anglickém jazyce

Mitoxantrone therapy in rapidly worsening multiple sclerosis

Popis výsledku anglicky

The aim of the study was to asses the effect and safety of mitoxantrone (MX) therapy in patients with relapsing remitting and secondary progressive multiple sclerosis (MS). Thirty-three patients (10 males, 23 females, mean age 48.5+/-9.9 years) with relapsing remitting and secondary progressive MS were followed. The disability was evaluated using Expanded Disability Status Scale (EDSS). The mean time period from the onset to secondary progressive course of the disease was 9.3+/-9.8 years. Patients, whose disability progression increased by one or more EDSS points per one year, and who did not respond to other therapy, were treated with mitoxantrone. Patients were treated once monthly with intravenous administration of mitoxantrone 12 mg/m2 (not exceeding the maximum cumulative dose of 140 mg/m2) and methylprednisolone 1000 mg. Six pulses were administered in each patient. EDSS score was measured at the beginning of the treatment and after twelve months. Disability progression was evalu

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2005

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bratislavské lekárske listy

ISSN

0006-9248

e-ISSN

—

Svazek periodika

106

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

3

Strana od-do

141-143

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—